These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA. Sun LQ; Wang L; Gerlach WL; Symonds G Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887 [TBL] [Abstract][Full Text] [Related]
11. Assessment of an anti-HIV-1 combination gene therapy strategy using the antisense RNA and multimeric hammerhead ribozymes. Ramezani A; Ma XZ; Ameli M; Arora A; Joshi S Front Biosci; 2006 Sep; 11():2940-8. PubMed ID: 16720366 [TBL] [Abstract][Full Text] [Related]
12. Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines. Sun LQ; Warrilow D; Wang L; Witherington C; Macpherson J; Symonds G Proc Natl Acad Sci U S A; 1994 Oct; 91(21):9715-9. PubMed ID: 7937878 [TBL] [Abstract][Full Text] [Related]
13. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design. Tabler M; Homann M; Tzortzakaki S; Sczakiel G Nucleic Acids Res; 1994 Sep; 22(19):3958-65. PubMed ID: 7937118 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and mode of action of hammerhead and hairpin ribozymes against various HIV-1 target sites. Hotchkiss G; Maijgren-Steffensson C; Ahrlund-Richter L Mol Ther; 2004 Jul; 10(1):172-80. PubMed ID: 15233952 [TBL] [Abstract][Full Text] [Related]
15. The subcellular localization and length of hammerhead ribozymes determine efficacy in human cells. Hormes R; Homann M; Oelze I; Marschall P; Tabler M; Eckstein F; Sczakiel G Nucleic Acids Res; 1997 Feb; 25(4):769-75. PubMed ID: 9016627 [TBL] [Abstract][Full Text] [Related]
16. A chimeric tRNA(Lys3)-ribozyme inhibits HIV replication following virion assembly. Westaway SK; Larson GP; Li S; Zaia JA; Rossi JJ Nucleic Acids Symp Ser; 1995; (33):194-9. PubMed ID: 8643367 [TBL] [Abstract][Full Text] [Related]
17. Inhibition of HIV-1 replication by retroviral vectors expressing monomeric and multimeric hammerhead ribozymes. Ramezani A; Ding SF; Joshi S Gene Ther; 1997 Aug; 4(8):861-7. PubMed ID: 9338016 [TBL] [Abstract][Full Text] [Related]
18. RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model. Bai J; Banda N; Lee NS; Rossi J; Akkina R Mol Ther; 2002 Dec; 6(6):770-82. PubMed ID: 12498773 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of human immunodeficiency virus type 1 replication by nuclear chimeric anti-HIV ribozymes in a human T lymphoblastoid cell line. Michienzi A; Conti L; Varano B; Prislei S; Gessani S; Bozzoni I Hum Gene Ther; 1998 Mar; 9(5):621-8. PubMed ID: 9551610 [TBL] [Abstract][Full Text] [Related]
20. A chimeric human immunodeficiency virus type 1 (HIV-1) minimal Rev response element-ribozyme molecule exhibits dual antiviral function and inhibits cell-cell transmission of HIV-1. Yamada O; Kraus G; Luznik L; Yu M; Wong-Staal F J Virol; 1996 Mar; 70(3):1596-601. PubMed ID: 8627679 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]